Expertise in
12
conditions

Dr. Elber Camacho

Hematology
Bucher Hematology/Oncology Inc.
1180 N Indian Canyon Dr Ste E218, 
Palm Springs, CA 
Expertise in
12
conditions
Bucher Hematology/Oncology Inc.
1180 N Indian Canyon Dr Ste E218, 
Palm Springs, CA 

Overview

Elber Camacho is a Hematologist in Palm Springs, California. Dr. Camacho is highly rated in 12 conditions, according to our data. His top areas of expertise are Breast Cancer, Essential Thrombocythemia, Paget Disease of the Breast, and Hodgkin Lymphoma.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

Bucher Hematology/Oncology Inc.
1180 N Indian Canyon Dr Ste E218, Palm Springs, CA 92262

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Sero-Epidemiologic Survey and Cost Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients
A Sero-Epidemiologic Survey and Cost Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients
Enrollment Status: Completed
Publish Date: July 03, 2023
View 7 Less Clinical Trials

3 Total Publications

An unusual case of primary acinar cell carcinoma of the liver and its treatment.
An unusual case of primary acinar cell carcinoma of the liver and its treatment.
Journal: Journal of gastrointestinal oncology
Published: October 12, 2019
Similar Doctors
Expertise in
129
conditions
Dr. Henry Tsai
Hematology
Expertise in
129
conditions
Dr. Henry Tsai
Hematology

Eisenhower Health

39000 Bob Hope Dr, 
Rancho Mirage, CA 
 (9.7 miles away)
760-346-7655
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Henry Tsai is a Hematologist in Rancho Mirage, California. Dr. Tsai is highly rated in 129 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Chronic Familial Neutropenia, Agranulocytosis, Bone Marrow Aspiration, and Advanced Bronchoscopy.

Expertise in
33
conditions
Dr. Iliana Popescu
Hematology
Expertise in
33
conditions
Dr. Iliana Popescu
Hematology

Eisenhower Lucy Curci Cancer Center

39000 Bob Hope Dr, 
Rancho Mirage, CA 
 (9.7 miles away)
760-346-7655
Languages Spoken:
English
See accepted insurances

Iliana Popescu is a Hematologist in Rancho Mirage, California. Dr. Popescu is highly rated in 33 conditions, according to our data. Her top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Breast Cancer, and Paget Disease of the Breast.

Expertise in
26
conditions
Dr. Allison Winter
Hematology | Oncology
Expertise in
26
conditions
Dr. Allison Winter
Hematology | Oncology

Cleveland Clinic

400 Craven Rd, 
San Marcos, CA 
 (60.9 miles away)
216-444-2200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Allison Winter is a Hematologist and an Oncologist in San Marcos, California. Dr. Winter is highly rated in 26 conditions, according to our data. Her top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Elber Camacho

How do I make an appointment with Dr. Elber Camacho?

You can book an appointment with Dr. Elber Camacho by calling their office at 760-416-4880. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Elber Camacho a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Elber Camacho is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Elber Camacho specialize in?

While Dr. Elber Camacho is a Hematology, they have specific expertise in Breast Cancer, Essential Thrombocythemia, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Elber Camacho participate in research or clinical trials?

Yes. Dr. Elber Camacho has published 3 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Elber Camacho's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Elber Camacho accept my insurance?

Dr. Elber Camacho accepts most major insurance plans, including Anthem BCBS and Blue Shield of California. We recommend calling the office directly at 760-416-4880 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Camacho's expertise for a condition
ConditionClose
      View All 12 Advanced Conditions
      View All 82 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile